BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 14967076)

  • 1. Non-small-cell lung cancer in elderly patients: influence of age on vinorelbine oral pharmacokinetics.
    Puozzo C; Gridelli C
    Clin Lung Cancer; 2004 Jan; 5(4):237-42. PubMed ID: 14967076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral versus intravenous vinorelbine: clinical safety profile.
    Gebbia V; Puozzo C
    Expert Opin Drug Saf; 2005 Sep; 4(5):915-28. PubMed ID: 16111453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine.
    Variol P; Nguyen L; Tranchand B; Puozzo C
    Eur J Clin Pharmacol; 2002 Oct; 58(7):467-76. PubMed ID: 12389069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
    Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial.
    Hirsh V; Desjardins P; Needles BM; Rigas JR; Jahanzeb M; Nguyen L; Zembryki D; Leopold LH
    Am J Clin Oncol; 2007 Jun; 30(3):245-51. PubMed ID: 17551300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial.
    Gridelli C; Manegold C; Mali P; Reck M; Portalone L; Castelnau O; Stahel R; Betticher D; Pless M; Pons JT; Aubert D; Burillon JP; Parlier Y; De Marinis F
    Eur J Cancer; 2004 Nov; 40(16):2424-31. PubMed ID: 15519515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.
    Clarke SJ; Boyer MJ; Millward M; Underhill C; Moylan E; Yip D; White S; Childs A; Beale P; Latz J; Suri A; Iglesias JL
    Lung Cancer; 2005 Sep; 49(3):401-12. PubMed ID: 15923057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer.
    Gauvin A; Pinguet F; Culine S; Astre C; Gomeni R; Bressolle F
    Clin Cancer Res; 2000 Jul; 6(7):2690-5. PubMed ID: 10914711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin and ifosfamide with various doses of vinorelbine (navelbine) in advanced non-small lung cancer.
    Souquet PJ; Fournel P; Bohas CH; Fortune IC; Chatte G
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):8-10. PubMed ID: 8610239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I-phase II study of vinorelbine with cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer.
    Masters GA; Drinkard LC; Hoffman PC; Lane N; Watson S; Samuels BL; Bitran JD; Golomb HM; Vokes EE
    Cancer J Sci Am; 1995; 1(4):288-94. PubMed ID: 9166490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).
    Wakelee HA; Middleton G; Dunlop D; Ramlau R; Leighl N; Hao D; Lopez-Anaya A; Zatloukal P; Jacobs CD
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):815-24. PubMed ID: 22057854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.
    Reck M; Macha HN; Del Barco S; Cornes P; Vaissière N; Morand M; Riggi M; Abratt R
    Lung Cancer; 2009 Jun; 64(3):319-25. PubMed ID: 19095327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC.
    Lena MD; Ramlau R; Hansen O; Lorusso V; Wagner L; Barni S; Cristovao MM; Huber R; Alberola V; Mitrovic M; Colin C; Gasmi J
    Lung Cancer; 2005 Apr; 48(1):129-35. PubMed ID: 15777980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small cell lung cancer (NSCLC): a feasibility study.
    Beckmann G; Fietkau R; Huber RM; Kleine P; Schmidt M; Semrau S; Aubert D; Fittipaldo A; Flentje M
    Onkologie; 2006 Apr; 29(4):137-42. PubMed ID: 16601369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Burris HA; Morrissey LH; Thomas M; Erland JB; Butts JA; Joseph G; Kalman L; Greco FA
    Cancer J; 2000; 6(3):151-6. PubMed ID: 10882330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design.
    Khayat D; Rixe O; Brunet R; Goupil A; Bugat R; Harousseau JL; Ifrah N; Puozzo C
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):193-205. PubMed ID: 15160284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10.
    Pepe C; Hasan B; Winton TL; Seymour L; Graham B; Livingston RB; Johnson DH; Rigas JR; Ding K; Shepherd FA;
    J Clin Oncol; 2007 Apr; 25(12):1553-61. PubMed ID: 17442999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage therapy with vinorelbine in advanced non-small-cell lung cancer: a retrospective review of the Fox Chase Cancer Center experience and a review of the literature.
    Devlin JG; Langer CJ
    Clin Lung Cancer; 2007 Mar; 8(5):319-26. PubMed ID: 17562231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy with cisplatin and vinorelbine for elderly patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC).
    Pereira JR; Martins SJ; Nikaedo SM; Ikari FK
    BMC Cancer; 2004 Sep; 4():69. PubMed ID: 15456520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: results of a pharmacokinetic study.
    Kitzen JJ; Puozzo C; de Jonge MJ; Brandely M; Verweij J
    Eur J Cancer; 2010 Jan; 46(2):266-9. PubMed ID: 19944596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.